Eisai Co. Ltd. and Ajinomoto Co. Inc. announced this week the establishment of EA Pharma Co. Ltd., based on the integration agreement signed by both companies on October 15 of last year.
EA Pharma will be formed by Eisai splitting off a portion of its gastrointestinal disease treatment business and the integration with Ajinomoto’s subsidiary, Ajinomoto Pharmaceuticals, effective April 1.
On the specified date, Eisai’s gastrointestinal disease business, which has been operating for more than 60 years, and Ajinomoto Pharmaceuticals, focusing on amino acids, will be combined to form EA Pharma, conducting all future business under that name. The newly formed company will be a gastrointestinal specialty pharma with a wide variety of departments, including research and development, production and logistics and sales and marketing.
EA Pharma will be dedicated to forming an Enterprise Architecture (EA) that will develop new innovative products through the combination of knowledge the two companies bring.
Eisai and Ajinomoto announce newly formed EA Pharma
Alerts Sign-up